drugset
drugset / Trial / NCT06650605

Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma

NCT06650605 ↗

Phase 1 Completed 7 enrolled Theragnostics Ltd
NaSingle-groupOpen-labelTreatment

Summary

Phase I open-label trial of 123I-ATT001 monotherapy and in combination with treatment therapies in subjects with relapsed glioblastoma.

Timeline

Start
2024-07-04
Primary completion
2026-03-01
Completion
2026-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 123I-ATT001 Unknown — —

Indications

glioblastoma